Background
Methods
Results
Patients
Hospital and treatments
Provinces | LC patients treated with RT | LC patients treated with RT (%) | Patients diagnosed with LC | RT rate (%)*
|
---|---|---|---|---|
1 | 21 (R 7 P 14) | 3 (R 33 P 67) | 244 | 9 |
2 | 54 (R 40 P 14) | 9 (R 74 P 26) | 458 | 12 |
3 | 70 (R 32 P 38) | 11 (R 46 P 54) | 305 | 23 |
4 | 87 (R 77 P 10) | 14 (R 89 P 11) | 336 | 26 |
5 | 48 (R 28 P 20) | 8 (R 58 P 42) | 183 | 26 |
6 | 48 (R 39 P 9) | 8 (R 81 P 19) | 244 | 20 |
7 | 132 (R 76 P 56) | 22 (R 58 P 42) | 580 | 23 |
8 | 150 (R 57 P 93) | 25 (R 38 P 62) | 701 | 21 |
Total | 610 (R 356 P 254) | 100% (R 58 P 42) | 3051 | 20 |
NSCLC N = 494 (81%) | SCLC N = 116 (19%) | ||||||
---|---|---|---|---|---|---|---|
Stage | N (%) radical | N (%) palliative | Total (%) | Stage | N (%) radical | N (%) palliative | Total (%) |
I
| 17 (6.2) | 4 (2) | 21 (4.2) | ||||
II
| 33 (12.1) | 8 (3.7) | 41 (8.3) |
Limited
| 82 (71) | - | 82 (71) |
III
| 179(65.3) | 125 (57) | 304 (61.5) | ||||
IV
| 45 (16.4) | 83 (37.3) | 128 (26) |
Extended
| - | 34 (29) | 34 (29) |
n = 610
| 274 (55.4) | 220 (44.6) | 494 (100) | 82 (71) | 34 (29) | 116 (100) |
Associated chemotherapy | Regimen | ||||
---|---|---|---|---|---|
Patients (%) | Patients (%) | ||||
NSCLC | SCLC | NSCLC | SCLC | ||
No
| 163 (33) | 16 (14) |
CDDP + Taxol
| 15 (3) | - |
Sequential
| 153 (31) | 35 (30) |
Carbo + Taxol
| 153 (31) | - |
Concomitant
| 153 (31) | 59 (51) |
CDDP + GMZ
| 84 (17) | 2 (2) |
Both
| 25 (5) | 6 (5) |
CDDP + VNB
| 84 (17) | 2 (2) |
Total
| 494 (100) | 116 (100) |
CDDP + VP-16
| 15 (3) | 53 (46) |
Carbo + VP-16
| 15 (3) | 52 (45) | |||
Other
| 128 (26) | 7 (5) | |||
Total
| 494 (100) | 116 (100) |
Radical radiotherapy in NSCLC
Radical radiotherapy in SCLC
Radical radiotherapy in NSCLC | |||||||||
---|---|---|---|---|---|---|---|---|---|
Histology (%) | Stage (%) | RT dose (%) | RT delay (%) | Associated CT (%) | |||||
SCC
| 48.1 |
I
| 6.2 |
<60 Gy
| 26 |
<30 days
| 49.7 |
No
| 20.6 |
ADC
| 21.7 |
II
| 12.1 |
≥60 Gy
| 74 |
≥30 days
| 50.3 |
Seq
| 32.6 |
LCUC
| 17.5 |
III
| 65.3 |
Conc
| 41.7 | ||||
Others
| 12.7 |
IV
| 16.4 |
Both
| 5.1 | ||||
Radical radiotherapy in SCLC
| |||||||||
RT dose (%)
|
RT delay (%)
|
Associated CT (%)
| |||||||
<45 Gy
| 3 |
<30 days
| 33 |
No
| 0 | ||||
≥45 Gy
| 97 |
≥30 days
| 67 |
Sequential
| 26 | ||||
Concomitant
| 63 | ||||||||
Both
| 11 |
Palliative radiotherapy (NSCLC and SCLC)
Radiotherapy schedule | Total (%) |
---|---|
Conventional fractionation (1.8-2 Gy)
| 16.5% |
3 fractions x 400 cGy
| 0.4% |
15 fractions x 300 cGy
| 10.3% |
10 fractions x 300 cGy
| 44.6% |
5 fractions x 400 cGy
| 12.9% |
2 fractions x 850 cGy
| 9.9% |
1 fraction x 800 cGy
| 1.8% |
Hyperfractionation
| 0.4% |
Other
| 3.2% |
Comparative study
Province | Histology (%) | Stage (%) | |||||
---|---|---|---|---|---|---|---|
SCC | ADC | LCUC | Others NSCLC | SCLC | Early (I-II) | Advanced (III-IV) | |
1
| 33.3 | 11.1 | 0 | 33.3 | 22.2 | 24.9 | 75.1 |
2
| 28.3 | 28.3 | 19.6 | 13 | 10.9 | 25 | 75 |
3
| 38.3 | 18.3 | 20 | 3.3 | 20 | 2 | 97.9 |
4
| 31.1 | 13.5 | 29.7 | 2.7 | 23 | 13 | 87 |
5
| 29.3 | 4.9 | 22 | 31.7 | 12.2 | 12.9 | 87.1 |
6
| 57.1 | 21.4 | 2.4 | 2.4 | 16.7 | 11.2 | 88.9 |
7
| 33.3 | 19.8 | 4.2 | 25 | 17.7 | 8.5 | 91.4 |
8
| 46.6 | 13.6 | 10.2 | 2.3 | 27.3 | 10.7 | 89.4 |
Province
|
Fractionation (%)
|
Associated CT (%)
| |||||
Conventional (1.8-2 Gy)
|
Other
|
No
|
Yes
| ||||
1
| 50 | 50.1 | 47.1 | 52.9 | |||
2
| 63.9 | 36.2 | 30.4 | 69.6 | |||
3
| 45.9 | 54 | 15.5 | 84.4 | |||
4
| 90.7 | 9.4 | 13.9 | 86.1 | |||
5
| 54.8 | 45.3 | 56.1 | 43.9 | |||
6
| 92.9 | 7.2 | 10.8 | 89.2 | |||
7
| 46.9 | 52.9 | 47.9 | 52.2 | |||
8
| 53.8 | 46.2 | 31.9 | 68.2 |
Dose (%) | Associated CT (%) | Stage (%) | Intent (%) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
VARA′04
| VARA ′07 |
VARA′04
| VARA ′07 |
VARA′04
| VARA′07 |
VARA′04
| VARA´07 | |||||||
NSCLC R
|
<60 Gy
|
147 (77.4)
| 136 (27.5) |
No
|
106 (25.9)
| 189 (31) |
NSCLC
|
I/II/III
|
332 (90)
| 415 (84) |
NSCLC
|
R
|
212 (63.1)
| 274 (55.4) |
≥60 Gy
*
|
43 (22.6)
| 358 (72.5) |
Yes
**
|
303 (74.1)
| 421 (69) |
IV
#
|
37 (10)
| 79 (16) |
P
##
|
124 (36.9)
| 220 (44.6) | |||
SCLC R
|
<45 Gy
|
33 (54.1)
| 1 (1.2) |
SCLC
|
LS
|
54 (79.1)
| 82 (71) |
SCLC
|
R
|
54 (79.1)
| 82 (71) | |||
≥45 Gy
*
|
28 (45.9)
| 115 (98.8) |
ES
§
|
14 (20.9)
| 34 (29) |
P
§
|
14 (20.9)
| 34 (29) | ||||||
Age (years)
§
|
Gender (%)
|
ECOG (%)
|
Radiation rate (%)
*
| |||||||||||
VARA′04
|
VARA′07
|
VARA′04
|
VARA′07
|
VARA′04
|
VARA´07
|
VARA´04
|
VARA′07
| |||||||
64,6 ± 10,7
| 66 ± 10 | ♀ |
33 (8)
| 55 (9) | 0 §§
|
94 (39.8)
| 141 (43.9) |
416 (16)
| 610 (20) | |||||
♂ ^
|
383 (92)
| 555 (91) | 1 |
85 (36)
| 131 (40.7) | |||||||||
2 |
36 (15.3)
| 40 (12.5) | ||||||||||||
3 |
18 (7.6)
| 7 (2.2) | ||||||||||||
4 |
3 (1.3)
| 2 (0.7) |
Study | Age | Gender (%) | Histology (%) | Stage (%) | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
♂ | ♀ | SCC | ADC | LCUC | SCLC | I | II | III | IV | LS | ES | ||
Salmerón 2012[18] | 67 | 90 | 10 | 37 | 20 | 8 | 16 | - | - | - | - | - | - |
Escuín 2009[19] | 70 | - | - | 38 | - | - | 20 | - | - | - | - | - | - |
Prim 2010[20] | 67 | 93 | 7 | 39 | 19 | 10 | 20 | 10 | 9 | 34 | 47 | 31 | 69 |
Escuín 2006[21] | 68 | 89 | 11 | 79 CPNCP | 21 | 20 | 4 | 37 | 35 | 37 | 61 | ||
Hernández 2004[22] | 68 | 85 | 15 | 38 | 17 | 12 | 30 | - | - | - | - | - | - |
Santos-M 2005[23] | 67 | 89 | 11 | 33 | 30 | 4 | 13 | 21 | 35 | 42 | 44 | 55 | |
Estrada 2007[24] | 67 | 90 | 10 | 24 | 17 | 29 | 19 | 24 | 4 | 27 | 41 | - | - |
Alonso-F 2005[25] | 67 | 92 | 8 | 58 | 29 | 5 | 19 | 27 | 7 | 35 | 31 | 47 | 53 |
VARA-II
|
66
|
91
|
8
|
37
|
17
|
15
|
19
|
4
|
8
|
61
|
26
|
71
|
29
|